Quinidine sulfate Rx
Generic Name and Formulations:
Quinidine sulfate 300mg; ext-rel tabs.
Various generic manufacturers
Indications for Quinidine sulfate:
Atrial and ventricular arrhythmias (see literature).
Take with food and in an upright position. 300–600mg every 8–12 hrs.
Complete AV or bundle branch block or other severe intraventricular conduction defects. Myasthenia gravis. Arrhythmias due to digitalis intoxication. Aberrant impulses, abnormal rhythms due to escape mechanisms.
Atrial flutter; digitalize first. Incomplete AV block. Marginally compensated cardiovascular disease. Heart failure. Hypotension. Renal or hepatic dysfunction. Monitor blood, liver and kidney function in long-term use. Monitor ECG and serum levels if dose is over 2.5g/day. Pregnancy (Cat.C). Nursing mothers.
Toxicity increased by amiodarone, cimetidine, ranitidine, diuretics, carbonic anhydrase inhibitors, sodium bicarbonate, verapamil, diltiazem. Potentiates anticoagulants, anticholinergics, neuromuscular blocking agents, phenothiazines, reserpine, timolol. Increases digitalis serum levels. Plasma levels decreased by barbiturates, hydantoins, rifampin, nifedipine.
Class I antiarrhythmic.
Nausea, vomiting, abdominal pain, diarrhea, new or exacerbated arrhythmias, heart block, syncope, cinchonism, headache, blood dyscrasias, hypotension, flushing, impaired hearing and vision, allergic reactions, hepatic dysfunction.
Formerly known under the brand names Cin-quin, Quinidex, Quinora.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|